### **Overview** Acutaas Chemicals Ltd (formerly known as **Ami Organics Limited**) is a research and development-driven global specialty chemicals manufacturer headquartered in Surat, Gujarat, India. The company rebranded in 2025 to reflect its strategic evolution from a pharmaceutical intermediates player into a diversified high-performance specialty chemicals company, serving next-generation industries such as **semiconductors**, **battery chemicals**, **pharmaceuticals**, **agrochemicals**, and **cosmetics**. The company is structured around three core business segments: 1. **Advanced Pharmaceutical Intermediates (APIs & CDMO)** 2. **Specialty Chemicals** – segmented into: - Battery Chemicals - Semiconductor Chemicals - Commodity & Niche Specialty Chemicals (e.g., parabens, methyl salicylate, KSMs) 3. **Contract Development and Manufacturing Organization (CDMO)** It operates a globally integrated business model with **74% of revenue from exports** and customers across **over 55 countries**, maintaining long-term partnerships with over 30 clients for more than a decade. --- ### **Strategic Transformation and Growth Pillars** #### **Rebranding and Strategic Pivot** In **September 2025**, the company rebranded as **Acutaas Chemicals Limited**, signaling a broader focus on **high-barrier, high-growth sectors** like **semiconductor-grade photoresists** and **battery electrolyte additives**. The shift aligns with global supply chain diversification (“China+1”) and demand for sustainable, high-purity, and technologically advanced chemical solutions. The company is now positioned as a **pioneer in India** in two critical domains: - **First Indian manufacturer of semiconductor-grade photoresist chemicals** (via **Baba Fine Chemicals**, its subsidiary). - **First non-Chinese global player to develop and commercialize electrolyte additives for lithium-ion batteries** (e.g., **Vinylene Carbonate (VC)** and **Fluoroethylene Carbonate (FEC)**). --- ### **1. Advanced Pharmaceutical Intermediates & CDMO** **Strategic Importance:** Remains the **largest revenue contributor** and core strength, accounting for ~85% of total revenue in earlier years. #### **Key Highlights (Sep–Oct 2025):** - Recorded **₹8,540 million in revenue in FY25**, growing **50.4% YoY**, driven by **CDMO ramp-up** and **core intermediates business**. - Operates two **PMDA- and USFDA-compliant** manufacturing units in **Ankleshwar and Sachin**, with the Ankleshwar plant inaugurated in Dec 2023 as **one of India’s most automated advanced intermediates facilities**. - Uses **Distributed Control System (DCS)** and **Powder Transfer Systems (PTS)** for high-precision, low-risk manufacturing of **high-potency APIs**. - **Backward integrated** to the **basic chemical level** for over **90% of pharma intermediates**, ensuring cost control and supply security. - Holds **22+ process patents**, with many for key **generic APIs** and **New Chemical Entities (NCEs)**. - Serves **160+ customers globally**, including innovators like **Fermion (Orion Group)**. #### **CDMO Progress** - Multiple **CDMO projects** nearing completion with validation batches dispatched. - Commercial contribution expected **by end of FY26**, pending regulatory approvals. - A multi-million-euro long-term **exclusive supply agreement** signed with a global innovator for four new intermediates of a single API. - Target: **₹1,000 crore CDMO revenue by FY2028**, up from ₹80–90 crore. --- ### **2. Battery Chemicals** **Strategic Importance:** Emerging as a **key future growth engine**, aligned with global electrification and clean energy trends. #### **Key Developments (Aug–Oct 2025):** - Launched **Ami Organics Electrolytes Pvt. Ltd. (AOEPL)** in **2022** as a wholly owned subsidiary; now a significant R&D and commercial unit. - **First Indian and first non-Chinese company globally** to develop **VC and FEC** electrolyte additives at scale. - **6 customers** have approved plant-scale samples; **10+ products** in development, including for **solid-state batteries** and **next-gen Li-ion technologies**. - **Long-term supply agreements** secured for **VC and FEC**, supporting new capacity installations. - New **electrolyte additives plant** under construction at **Jhagadia** (Gujarat), with **commissioning expected in H2 FY26**. - **Capex investment of ₹250 crores FY26**, including pilot plant at **Sachin** and expansion of Jhagadia. - In **August 2025**, announced a **₹177 crore investment** in new battery chemicals capacity, targeting **2,000 metric tons each of VC and FEC**, with an expected **asset turnover of 1.5x** and **higher margins** than current specialty chemical operations. - Management confirms **commercial contracts from new products** expected from **FY27**. - **Production expected to begin in Q4 FY26**, following capacity expansion. --- ### **3. Semiconductor Chemicals** **Strategic Importance:** High-margin, high-barrier business with long-term growth potential. #### **Key Developments (Sep–Oct 2025):** - Entry via **55% acquisition of Baba Fine Chemicals (BFC)** in **2023**, the **only Indian manufacturer of semiconductor-grade photoresist chemicals**. - Capable of **ultra-high purity** (parts-per-billion level), essential for **advanced semiconductor manufacturing**. - Actively engaging with **Korea, Japan, and Taiwan** – key semiconductor hubs – with **samples dispatched and validation underway**. - **Indichem Inc.**, a **joint venture in South Korea** (75% Acutaas, 25% J & Materials Co. Ltd.), is **under construction** and expected to **contribute revenue from H2 FY27**. - Total investment in the JV: **KRW 30 billion (~₹185 crore)**. - **Meaningful revenue contributions not expected immediately** – early monetization likely in **2026–2027**. - R&D focused on **backend packaging materials** and **custom solutions for regional markets**. --- ## **Financial Performance and Guidance** | Metric | Performance (Latest) | |--------|-----------------------| | **FY25 Revenue** | ₹10,069 million (₹1,006.9 crore), **+40.3% YoY** | | **Q2 FY26 Revenue** | ₹306.2 crore, **+24.1% YoY** | | **Advance Pharma Intermediates (FY25)** | ₹8,540 million | | **Specialty Chemicals (FY25)** | ₹1,529 million | | **PBT / EBITDA Guidance (FY26)** | EBITDA margin of **28–30%**, revenue growth of **~25%** | | **Capex (H1 FY26)** | ₹141 crore | | **Total FY26 Capex Outlook** | ₹250 crore | | **Exports Share** | **74% of FY25 revenue** | --- ## **Manufacturing and Operational Excellence** ### **Facilities (Total: 5)** - **Sachin, Gujarat**: Pharma intermediates, R&D hub; **PMDA GMP certified**. - **Ankleshwar, Gujarat**: State-of-the-art automated pharma intermediates plant; **442 KL capacity**; DCS-enabled. - **Jhagadia, Gujarat**: Specialty & battery chemicals; **512 KL installed capacity**; dedicated lines for parabens, methyl salicylate. - **Greater Noida, Uttar Pradesh**: Semiconductor chemicals (Baba Fine Chemicals). - **Indichem JV, South Korea**: In construction – future semiconductor chemicals production. ### **Sustainability & ESG Leadership** - **EcoVadis Platinum (2025)** and **Gold (2024)** ratings. - **16 MW captive solar plant** operational; meeting most power needs at Ankleshwar and Jhagadia. - Additional **5 MW solar project under development** for Sachin. - **Zero Liquid Discharge (ZLD)** systems across all major units. - **Net Zero emissions by 2050** commitment. - Certifications: **ISMS 27001**, **SA8000:2014**, **ISO 9001/14001**, **Kosher**, **Halal**, and **Three Star Export House (DGFT)**. --- ## **Research & Development** ### **R&D Infrastructure** - **30+ specialized workstations**, 300+ sq. m. of lab space (Sachin & GIDC). - **R&D Team**: Over **130 professionals**, including **30+ Ph.D.s**. - **DSIR-recognized in-house R&D center**. - Advanced instruments: **LC-MS, GC-MS, ICP-MS, DSC, UV-Vis, IR, IC**, stability chambers. ### **Innovation & Process Technology** - **43 distinct reaction capabilities** across pharmaceuticals, semiconductors, batteries, agrochemicals. - Leading in **continuous flow chemistry**, with capabilities in **plug flow**, **tubular**, and **microchannel reactors**. - Successfully commercialized multiple products using **flow reactors**, resulting in: - **3x higher capacity** - **5–7% cost savings** - **Reduced cycle time and solvent usage** - Filed **43+ process patents** (as of 2025); **10 granted**, including for **electrolyte additives** and **photoresist chemicals**. - Early entrant in **photochemistry** (R&D phase) and **gravity flow systems**. --- ## **Growth Strategy** ### **Vision 2030** - Transition from a **India-centric pharma intermediates supplier** to a **global leader in next-gen specialty chemicals**. - Become a **trusted, high-tech solutions provider** in **battery**, **semiconductor**, and **innovator-driven CDMO** markets. ### **Strategic Priorities** 1. **Portfolio Evolution**: Phasing out **low-margin products**, improving **product mix**. 2. **Technology Leadership**: Adopting **continuous manufacturing**, **automation**, **digitalization**. 3. **Geographic Expansion**: Strengthening **U.S., EU, Japan, Korea, Taiwan** relationships. 4. **Capital Allocation**: Focused on **battery chemicals**, **semiconductors**, and **CDMO**. 5. **Sustainable Advantage**: **Backward integration**, **domestic sourcing (70%+)**, **cost leadership**, and **patented processes**.